A Glimmer of Hope in the New Cabinet?

Here’s the first bit if good news about the new cabinet.  A possible nominee for the Food and Drug Administration, Jim O’Neill, is a “legalization proponent.”  Any port in a storm I guess.  Here’s more:


Bloomberg News reported on Wednesday that Jim O’Neill, a marijuana legalization proponent, is being considered to lead the U.S. Food and Drug Administration (FDA) under the Trump administration. If O’Neill is formally appointed and then confirmed by the U.S. Senate as commissioner of food and drugs, it could bode extremely well for future efforts to reform federal marijuana laws.

The FDA is responsible for conducting the scientific analyses of cannabis’s harms and medical benefits that rescheduling rulings are based on. Before the most recent denial of a rescheduling petition by the U.S. Drug Enforcement Administration (DEA) in August, FDA concluded that marijuana has a “high potential for abuse” and “no currently accepted medical use in treatment.” But there is in fact a lot of scientific research showing marijuana to be medically beneficial and relatively safe. Presumably, under O’Neill’s leadership, FDA would more seriously consider and weigh that literature before making future reclassification recommendations.

O’Neill, a close associate of tech financier and Trump transition team member Peter Thiel, has been active in the movement to reform marijuana laws. For example, he was a founding member of the board of directors of the Coalition for Cannabis Policy Reform, a California-based legalization advocacy organization.
. . .
With O’Neill at FDA, however, marijuana law reformers would have a key ally in position to help shape the Trump administration’s position on cannabis policy.
. . .
Medical cannabis advocates are hopeful that O’Neill would apply his consumer freedom philosophy to natural, plant-based medicines in addition to synthetic pharmaceuticals. Mike Liszewski of Americans for Safe Access told Marijuana.com that FDA’s current approval process for botanicals is “unworkable” and that as a result, very few have been approved.

“O’Neill’s appointment could lead to an overhaul of rules pertaining to botanical medicine, which could create a much friendlier environment for research and approval of cannabis and other botanicals,” he said.

So the new Trump administration is not all bad news, just mostly. We are keeping track and will keep you informed.

Find more detail at the complete original post HERE.

Can’t let this go — that’s a picture of Mr. O’Neill. No diversity (yet — ever?) in the incoming administration. No surprise there, I’m sorry to say.  Hail Mary Jane’s position is that cannabis should be removed from the CSA leaving the issue up to the various states.  That will, eventually, get us to re-legalization.

[image:  CNBC.com]


Featured Partner: Meet All Your Local Marijuana Needs (Buy Sell Buds) Anonymously In Real-Time For FREE

Leafedin – Weed App – Find Weed Near You! Meet Any of Your Marijuana Product or Labor Needs Locally in Real-Time! Free Anonymous Map Weed App, Works On Any Device, Sign-Up In Seconds and Find Bud Connects Marijuana Work or Labor, New Clients, etc INSTANTLY!


Author: DavidB

a heathen, but hopefully not an unenlightened one

Share This Post On

Pin It on Pinterest

Share This